Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0001051
DC FieldValue
dc.titleAnkyrin-B syndrome: Enhanced cardiac function balance by risk of cardiac death and premature senescence
dc.contributor.authorMohler P.J.
dc.contributor.authorHealy J.A.
dc.contributor.authorXue H.
dc.contributor.authorPuca A.A.
dc.contributor.authorKline C.F.
dc.contributor.authorAllingham R.R.
dc.contributor.authorKranias E.G.
dc.contributor.authorRockman H.A.
dc.contributor.authorBennett V.
dc.date.accessioned2019-11-08T00:58:22Z
dc.date.available2019-11-08T00:58:22Z
dc.date.issued2007
dc.identifier.citationMohler P.J., Healy J.A., Xue H., Puca A.A., Kline C.F., Allingham R.R., Kranias E.G., Rockman H.A., Bennett V. (2007). Ankyrin-B syndrome: Enhanced cardiac function balance by risk of cardiac death and premature senescence. PLoS ONE 2 (10) : e1051. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0001051
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161863
dc.description.abstractHere we report the unexpected finding that specific human ANK2 variants represent a new example of balanced human variants. The prevalence of certain ANK2 (encodes ankyrin-B) variants range from 2 percent of European individuals to 8 percent in individuals from West Africa. Ankyrin-B variants associated with severe human arrhythmia phenotypes (eg E1425G, V1516D, R1788W) were rare in the general population. Variants associated with less severe clinical and in vitro phenotypes were unexpectedly common. Studies with the ankyrin-B+/- mouse reveal both benefits of enhanced cardiac contractility, as well as costs in earlier senescence and reduced lifespan. Together these findings suggest a constellation of traits that we term "ankyrin-B syndrome", which may contribute to both aging-related disorders and enhanced cardiac function. � 2007 Mohler et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectankyrin
dc.subjectankyrin b
dc.subjectunclassified drug
dc.subjectANK2 protein, human
dc.subjectAnk2 protein, mouse
dc.subjectankyrin
dc.subjectAfrica
dc.subjectanimal cell
dc.subjectanimal experiment
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectdisease association
dc.subjectdisease severity
dc.subjectEurope
dc.subjectfemale
dc.subjectgenetic variability
dc.subjectgenotype
dc.subjectheart arrhythmia
dc.subjectheart death
dc.subjectheart disease
dc.subjectheart function
dc.subjectheart muscle cell
dc.subjectheart muscle contractility
dc.subjecthuman
dc.subjecthuman cell
dc.subjectin vitro study
dc.subjectlifespan
dc.subjectmouse
dc.subjectnonhuman
dc.subjectnucleotide sequence
dc.subjectphenotypic variation
dc.subjectpremature aging
dc.subjectprevalence
dc.subjectrisk assessment
dc.subjectsenescence
dc.subjectaging
dc.subjectanimal
dc.subjectC57BL mouse
dc.subjectcell aging
dc.subjectdeath
dc.subjectechocardiography
dc.subjectgenetics
dc.subjectheart contraction
dc.subjectheart disease
dc.subjectmethodology
dc.subjectpathology
dc.subjectphenotype
dc.subjectphysiology
dc.subjectrisk
dc.subjectsyndrome
dc.subjectAging
dc.subjectAnimals
dc.subjectAnkyrins
dc.subjectCell Aging
dc.subjectDeath
dc.subjectEchocardiography
dc.subjectHeart Diseases
dc.subjectHumans
dc.subjectMice
dc.subjectMice, Inbred C57BL
dc.subjectMyocardial Contraction
dc.subjectPhenotype
dc.subjectRisk
dc.subjectSyndrome
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1371/journal.pone.0001051
dc.description.sourcetitlePLoS ONE
dc.description.volume2
dc.description.issue10
dc.description.pagee1051
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0001051.pdf2 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons